(119 days)
MagVenture TMS Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
The MagVenture TMS Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
The MagVenture TMS Therapy System is a transcranial magnetic stimulation device. Specifically, it is a computerized, electromechanical medical device that produces and delivers non-invasive magnetic fields to induce electrical currents targeting specific regions of the cerebral cortex.
Transcranial magnetic stimulation (TMS) is a non-invasive technique used to apply brief magnetic pulses to the brain. The pulses are administered by passing high currents through an electromagnetic coil placed adjacent to a patient's scalp.
The pulses generate an electric field in the underlying brain tissue. When this field surpasses a specific threshold and aligns appropriately with the brain's neuronal pathways, it induces localized axonal depolarization, leading to neuron activation in the targeted brain region.
The MagVenture TMS Therapy System represents an integrated system comprised of the following components:
- Magnetic Stimulator (MagPro Family)
- Coil for motor threshold determination: C-B60, C-B70
- Treatment Coils: Cool-B65, Cool-B70, Cool D-B80
- Accessories:
- Trolley with mounting for super flexible arm and coil holder arrangement)
- Patient head fixation
- Super flexible arm or Flow Arm for coil fixation
- Isolation transformer
- Cooler Unit
- Caps and Marking accessory (marking plate, pen, ruler) – Beam F3 or 5.5 cm Coil Placement
- Vacuum pump and Vacuum pillow with Pillow Case for patient head fixation (Optional)
- Treatment Chair (Optional)
- Coil Hub (Optional)
- MagVenture TMS Atlas Neuro Navigation System (Optional)
Except for the Beam F3 marking plate, all components have previously received FDA clearance. The MagVenture TMS Therapy System and its technological characteristics remain equivalent to those cleared under K150641, K171481, K171967, K173620, K193006 for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) indications.
This submission introduces the following modifications:
- Expanded Indications: Includes treatment for depressive episodes and comorbid anxiety symptoms in adult patients with MDD who have not responded satisfactorily to prior antidepressant medication.
- Coil Approval Expansion: All three MagVenture treatment coils are now included for MDD, MDD w/ comorbid anxiety symptoms, depressive episodes, and OCD treatment.
- Beam F3 Marking Method: Introduces the Beam F3 marking plate as an alternative to the standard 5.5 cm method for coil positioning in the dorsolateral prefrontal cortex (DLPFC).
All other aspects of the device compared to the currently marketed MagVenture TMS Therapy remain unchanged.
The provided FDA 510(k) clearance letter for the MagVenture TMS Therapy System does not contain any information about acceptance criteria or a study proving that the device meets those criteria, especially in the context of AI/algorithm performance.
This document is a traditional 510(k) submission, which focuses on demonstrating substantial equivalence to a legally marketed predicate device rather than presenting detailed performance study results against specific acceptance criteria for a new, AI-driven diagnostic or therapeutic system.
Here's a breakdown of why the requested information cannot be extracted from this document:
- Device Type: The MagVenture TMS Therapy System is a Transcranial Magnetic Stimulation device, an electromechanical medical device that physically delivers magnetic pulses. It is not an AI-driven diagnostic or therapeutic algorithm. The "AI" context in your prompt is not relevant to this specific device.
- Focus of 510(k): The core of this 510(k) summary is to demonstrate that the MagVenture TMS Therapy System, with its introduced modifications, is "substantially equivalent" to an existing predicate device (NeuroStar Advanced Therapy System, K230029). This is shown by comparing technological characteristics, indications for use, and treatment parameters, not by conducting novel clinical trials to establish its own efficacy against predefined acceptance criteria for AI performance.
- "Performance Data" Section (Page 16): This section explicitly states:
- "No clinical performance data were included in this submission."
- Performance testing summarized relates to electrical safety, electromagnetic compatibility (compliance with IEC standards), and quality/risk management (ISO standards).
- Computational modeling (SimNIBS v4.0.1) was used to compare electric field strength of coils, which is a physical characteristic, not a clinical efficacy or AI performance metric.
Therefore, I cannot provide the requested information based on the provided document. The document discusses the device's technical specifications and its equivalence to a predicate device, but not how it meets acceptance criteria for an AI or imaging-based clinical outcome.
Specifically, the following points from your request cannot be addressed as they pertain to AI/algorithm performance studies which are not described in this 510(k):
- Table of acceptance criteria and reported device performance (for AI performance): Not applicable. The "performance" discussed is electrical and safety compliance, not AI accuracy or efficacy.
- Sample size for test set and data provenance: No clinical test set data for algorithm performance is mentioned.
- Number of experts and qualifications for ground truth: No expert-driven ground truth establishment for AI is mentioned.
- Adjudication method: Not applicable.
- Multi-reader multi-case (MRMC) comparative effectiveness study: Not applicable, as there's no AI component or human-in-the-loop study discussed.
- Standalone (algorithm only) performance: Not applicable.
- Type of ground truth used: Not applicable in the context of AI/algorithm performance.
- Sample size for training set: No training set for an algorithm is mentioned.
- How ground truth for training set was established: Not applicable.
This 510(k) clearance is for a physical medical device, not an AI software.
FDA 510(k) Clearance Letter - MagVenture TMS Therapy System
Page 1
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
Doc ID # 04017.08.00
August 8, 2025
Tonica Elektronik A/S
℅ Kirstine Klitgaard Schou
Senior Medical Affairs Specialist
MagVenture A/S
Lucernemarken 15
Farum, DK-3520
Denmark
Re: K251119
Trade/Device Name: MagVenture TMS Therapy System
Regulation Number: 21 CFR 882.5805, 21 CFR 882.5802
Regulation Name: Repetitive Transcranial Magnetic Stimulation System
Regulatory Class: Class II
Product Code: OBP, QCI
Dated: July 11, 2025
Received: July 14, 2025
Dear Kirstine Klitgaard Schou:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
Page 2
K251119 - Kirstine Klitgaard Schou Page 2
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
Page 3
K251119 - Kirstine Klitgaard Schou Page 3
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
PAMELA D. SCOTT -S
Digitally signed by PAMELA D. SCOTT -S
Date: 2025.08.08 23:01:16 -04'00'
Pamela D. Scott
Assistant Director
DHT5B: Division of Neuromodulation and Physical Medicine Devices
OHT5: Office of Neurological and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
Indications for Use
510(k) Number (if known): K251119
Device Name: MagVenture TMS Therapy System
Indications for Use (Describe)
MagVenture TMS Therapy is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
The MagVenture TMS Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/23) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF
Page 5
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 1 of 12
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of 21 CFR §807.92:
Date Prepared: August 8, 2025
I. SUBMITTER
Tonica Elektronik A/S
Lucernemarken 15
DK-3520 Farum, Denmark
Tel: +45 4499 1544
Primary Contact: Kirstine Klitgaard Schou, Ph.D.
Senior Medical Affairs Specialist
Phone: + 45 6114 6675
E-mail: kks@magventure.com
Secondary Contact: Jan Kjøller
Head of Regulatory Affairs
Phone: +45 2489 9976
E-mail: jk@magventure.com
II. DEVICE
Device Trade Name: MagVenture TMS Therapy System
Classification Names:
- Repetitive transcranial magnetic stimulation system
- Transcranial magnetic stimulation system for neurological and psychiatric disorders and conditions.
Regulation: 21 CFR 882.5805, 21 CFR 882.5802
Regulatory Class: Class II
Device Panel: Neurological Therapeutic Devices
Product Classification Code: OBP, QCI
III. PREDICATE DEVICE
Predicate Manufacturer: Neuronetics
Predicate Trade Name: NeuroStar Advanced Therapy System
Predicate 510(k): K230029
Predicate Regulation: 21 CFR 882.5805, 21 CFR 882.5802
Predicate Product Code: OBP, QCI
Page 6
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 2 of 12
IV. DEVICE DESCRIPTION
The MagVenture TMS Therapy System is a transcranial magnetic stimulation device. Specifically, it is a computerized, electromechanical medical device that produces and delivers non-invasive magnetic fields to induce electrical currents targeting specific regions of the cerebral cortex.
Transcranial magnetic stimulation (TMS) is a non-invasive technique used to apply brief magnetic pulses to the brain. The pulses are administered by passing high currents through an electromagnetic coil placed adjacent to a patient's scalp.
The pulses generate an electric field in the underlying brain tissue. When this field surpasses a specific threshold and aligns appropriately with the brain's neuronal pathways, it induces localized axonal depolarization, leading to neuron activation in the targeted brain region.
The MagVenture TMS Therapy System represents an integrated system comprised of the following components:
- Magnetic Stimulator (MagPro Family)
- Coil for motor threshold determination: C-B60, C-B70
- Treatment Coils: Cool-B65, Cool-B70, Cool D-B80
- Accessories:
- Trolley with mounting for super flexible arm and coil holder arrangement)
- Patient head fixation
- Super flexible arm or Flow Arm for coil fixation
- Isolation transformer
- Cooler Unit
- Caps and Marking accessory (marking plate, pen, ruler) – Beam F3 or 5.5 cm Coil Placement
- Vacuum pump and Vacuum pillow with Pillow Case for patient head fixation (Optional)
- Treatment Chair (Optional)
- Coil Hub (Optional)
- MagVenture TMS Atlas Neuro Navigation System (Optional)
Except for the Beam F3 marking plate, all components have previously received FDA clearance. The MagVenture TMS Therapy System and its technological characteristics remain equivalent to those cleared under K150641, K171481, K171967, K173620, K193006 for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) indications.
Page 7
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
This submission introduces the following modifications:
- Expanded Indications: Includes treatment for depressive episodes and comorbid anxiety symptoms in adult patients with MDD who have not responded satisfactorily to prior antidepressant medication.
- Coil Approval Expansion: All three MagVenture treatment coils are now included for MDD, MDD w/ comorbid anxiety symptoms, depressive episodes, and OCD treatment.
- Beam F3 Marking Method: Introduces the Beam F3 marking plate as an alternative to the standard 5.5 cm method for coil positioning in the dorsolateral prefrontal cortex (DLPFC).
All other aspects of the device compared to the currently marketed MagVenture TMS Therapy remain unchanged.
V. INDICATIONS FOR USE STATEMENT
-
The MagVenture TMS Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.
-
The MagVenture TMS Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
VI. SUBSTANTIAL EQUIVALENCE DISCUSSION
The following tables covering product codes OBP and QCI compare the MagVenture TMS Therapy System to the predicate device with respect to indications for use and intended use, and technological characteristics including principles of operation, design and output stimulation parameters, and forms the basis for the substantial equivalence determination.
The new device is substantially equivalent to the predicate device (K230029). They have the same intended use and indications for use. Both devices use the same principles of operation to apply TMS treatment at a defined intensity as repetitive pulse trains delivered as brief rapidly alternating magnetic fields to induce electrical currents to the prefrontal cortex. They have substantially equivalent technological characteristics. Both devices represent integrated systems of components including TMS stimulator with software, electromagnetic coils for MT determination and treatment, coil fixture and positioning system and head support system. The operational procedures including system setup, patient preparations, motor threshold
Page 3 of 12
Page 8
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
determination, coil positioning and patient treatment with predefined treatment stimulation settings are substantially equivalent. Devices target the identical anatomical area of the brain. Minor identified differences in system components and output stimulation paraments do not raise different questions of safety and effectiveness than the primary predicate.
Substantial equivalence between the MagVenture TMS Therapy System and the NeuroStar Advanced Therapy System has been previously demonstrated in prior FDA clearances for the existing indications for use (K150641, K171481). The technological characteristics of the MagVenture TMS Therapy System are unchanged in this submission from those prior clearances.
The MagVenture TMS Therapy System has previously obtained FDA clearance for the treatment of major depressive disorder (MDD) in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode (K150641, K170114, K171481, K171967, K172667, K173620).
Page 4 of 12
Page 9
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 5 of 12
Table-1 Technological comparison with primary predicate for MDD w/ Comorbid Anxiety Symptoms (Product Code: OBP):
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Trade Name | MagVenture TMS Therapy System | NeuroStar Advanced Therapy System | Not applicable |
| Manufacturer | Tonica Elektronik A/S | Neuronetics Inc. | |
| 510(k) | K251119 | K230029 | |
| Product codes/Classification | OBP | OBP | Same |
| Regulation Numbers | 21 CFR 882.5805 | 21 CFR 882.5805 | Same |
CLINICAL CHARACTERISTICS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Indications for use | The MagVenture TMS Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. | The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. | Same |
| Intended Use | Major Depressive Disorder (MDD) and comorbid anxiety symptoms | Major Depressive Disorder (MDD) and comorbid anxiety symptoms | Same |
| Clinical Settings | Inpatient and outpatient settings including physician's offices and clinics, hospitals, and general medical/surgical hospitals | Inpatient and outpatient settings including physician's offices and clinics, hospitals, and general medical/surgical hospitals | Same |
| Target populations | Adult Patients | Adult Patients | Same |
| Treatment schedule | 5 days per week for 4-6 weeks Total of 20-30 treatment sessions plus 6 taper sessions over 3 weeks | 5 days per week for 4-6 weeks Total of 20-30 treatment sessions plus 6 taper sessions over 3 weeks | Same |
| Area of the brain to be stimulated | Left dorsolateral prefrontal cortex | Left dorsolateral prefrontal cortex | Same |
TREATMENT PARAMETERS – STANDARD TREATMENT
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Magnetic Field Intensity | 120% of MT | 120% of MT | Same recommended treatment parameters |
| Repetition Rate | 10 Hz | 10 Hz | |
| Train duration | 4 sec | 4 sec | |
| Inter-train interval | 11-26 sec | 11-26 sec |
Page 10
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 6 of 12
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| No of trains | 75 | 75 | |
| Pulses per session | 3000 | 3000 | |
| Session Duration | 18.75-37.5 min | 18.75-37.5 min |
TREATMENT PARAMETERS – THETA BURST
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Magnetic Field Intensity | 120% of MT with allowable adjustments | 80-120% MT with allowable adjustments | Same recommended treatment parameters |
| Train duration | 2 sec | 2 sec | |
| Inter-train interval | 8 sec | 8 sec | |
| Pulses per Burst | 3 | 3 | |
| Bursts per Second | 5 | 5 | |
| Inter-pulse Interval | 20 ms | 20 ms | |
| Session Duration | 3.15 | 3.15 | |
| Pulses Per Session | 600 | 600 |
COIL SPECIFICATIONS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Coil type | Figure-of-eight design with dual windings and an air core. | Figure-of eight- design with a ferromagnetic core | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Windings | Depending on coil variant: 2×75mm 2×97mm 2×95mm | 2×70mm | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Pulse Type | Biphasic | Biphasic | Same |
| Pulse width | 290 µs (±5%) | 185 µs (±10%) | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
Page 11
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Cooling | Forced liquid cooling | Air Cooled | Both methods of cooling are sufficient for the specific design. |
| Maximum Coil Temperature | 43°C | 44°C | Similar Both systems will automatically disable if this maximum temperature is reached |
TECHNOLOGICAL CHARACTERISTICS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Device components | 1. Mobile console 2. System software with GUI 3. Treatment chair 4. Head support system 5. Coil positioning system standard 5.5 cm method and Beam F3 method for determining treatment location and coil positioning 6. Same coil for both MT and treatment or MT coil and treatment coil 7. Coil Fixture 8. Data Management System | 1. Mobile console 2. System software with GUI 3. Treatment chair 4. Head support system 5. Coil positioning system standard 5 cm method and Beam F3 method for determining treatment location and coil positioning 6. Same Coil for both MT and treatment 7. Coil fixture 8. Data management system | Similar |
| Power Source | Power Supply Mobile console: 110Vac, 20A | Power Supply Mobile console: 110Vac, 20A | Same |
| Frequency range (Hz) at 100% | 0.1-30 (MagPro R30) and 0.1-100 (MagPro X100) | 1-30 | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Preset range of % MT | 0 – 140% | 25 – 140% | |
| Pulse train duration range (sec) | 1 – 33 | 1 – 20 | |
| Inter-train interval range (sec) | 0.1 – 120 (±2%) | 10 – 60 | |
| Available Stimulation Intensity in terms of Standard Motor | Ranging from 0 – 2.2 SMT depending on coil capabilities | Range: 0.22 - 2.08 SMT |
Page 7 of 12
Page 12
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Threshold (SMT) units | |||
| Peak magnetic field strength (T) at a depth of 2cm | Ranging from 0.46 – 0.55T depending on coil capabilities. | 0.5T | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Peak magnetic field gradient dB/dt (kT/s) at a depth of 2cm | Ranging from 9 – 12 kT/s depending on coil capabilities | 11 kT/s |
PERFORMANCE DATA
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Electrical Safety & Electromagnetic Compatibility | Complies with IEC60601-1 and IEC60601-1-2 | Complies with IEC60601-1 and IEC60601-1-2 | Same |
| Quality & Risk standards | Company complies with ISO 13485:2016 and ISO 14971:2019 | Company complies with ISO 13485:2016 and ISO 14971:2019 |
*SE: Substantial equivalent
Page 8 of 12
Page 13
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 9 of 12
Table-2. Technological comparison with primary predicate for OCD (Product Code: QCI):
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Trade Name | MagVenture TMS Therapy System | NeuroStar Advanced Therapy System | Not applicable |
| Manufacturer | Tonica Elektronik A/S | Neuronetics Inc. | |
| 510(k) | K251119 | K230029 | |
| Product codes/Classification | QCI | QCI | Same |
| Regulation Numbers | 21 CFR 882.5802 | 21 CFR 882.5802 | Same |
CLINICAL CHARACTERISTICS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Indications for use | The MagVenture TMS Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD) | The NeuroStar Advanced Therapy System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD) | Same |
| Intended use | Obsessive-Compulsive Disorder | Obsessive-Compulsive Disorder | Same |
| Clinical Settings | Inpatient and outpatient settings including physician's offices and clinics, hospitals, and general medical/surgical hospitals | Inpatient and outpatient settings including physician's offices and clinics, hospitals, and general medical/surgical hospitals | Same |
| Target populations | Adult Patients (ages 22-68) | Adult Patients (ages 22-70) | Similar. Age within ranges of predicate device. |
| Treatment schedule | Weeks 1-5: 1 treatment session per day for 5 days Week 6: 1 treatment session per day for 4 days Total of 29 treatment sessions | Weeks 1-5: 1 treatment session per day for 5 days Week 6: 1 treatment session per day for 4 days Total of 29 treatment sessions | Same |
| Area of the brain to be stimulated | Dorsomedial prefrontal cortex | Dorsomedial prefrontal cortex | Same |
TREATMENT PARAMETERS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Magnetic Field Intensity | 100% of MT (Tibialis Motor Cortex) | 100% of MT (leg motor cortex) | Same recommended treatment |
| Repetition Rate | 20 Hz | 20 Hz | parameters |
| Train duration | 2 sec | 2 sec | |
| Inter-train interval | 20 sec | 20 sec | |
| No of trains | 50 | 50 |
Page 9 of 12
Page 14
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 10 of 12
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Pulses per session | 2000 | 2000 | |
| Session Duration | 18.3 min | 18.3 min |
COIL SPECIFICATIONS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Coil type | Figure-of-eight design with dual windings and an air core. | Figure-of eight-design with a ferromagnetic core | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Windings | Depending on coil variant: 2×75mm 2×97mm 2×95mm | 2×70mm | |
| Pulse Type | Biphasic | Biphasic | Same |
| Pulse width | 290 µs (±5%) | 185 µs (±10%) | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Cooling | Forced liquid cooling | Air Cooled | Similar. Both methods of cooling are sufficient for the specific design. |
| Maximum Coil Temperature | 43°C | 44°C | Similar. Both systems will automatically disable if this maximum temperature is reached |
TECHNOLOGICAL CHARACTERISTICS
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Device components | 1. Mobile console 2. System software with GUI 3. Treatment chair 4. Head support system 5. Coil positioning system | 1. Mobile console 2. System software with GUI 3. Treatment chair 4. Head support system 5. Coil positioning system 6. Same Coil for both MT and treatment | Similar |
Page 10 of 12
Page 15
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
Page 11 of 12
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| 6. Same coil for both MT and treatment or MT coil and treatment coil 7. Coil Fixture 8. Data Management System | 7. Coil fixture 8. Data management system | ||
| Power Source | Power Supply Mobile console: 110Vac, 20A | Power Supply Mobile console: 110Vac, 20A | Same |
| Frequency range (Hz) at 100% | 0.1-30 (MagPro R30) and 0.1-100 (MagPro X100) | 1-30 | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Preset range of % MT | 0-140% | 25-140% | |
| Pulse train duration range (sec) | 1-33 | 1-20 | |
| Inter-train interval range (sec) | 0.1-120 (±2%) | 10-60 | |
| Available Stimulation Intensity in terms of Standard Motor Threshold (SMT) units | Ranging from 0 – 2.2 SMT depending on coil capabilities | Range: 0.22 - 2.08 SMT | |
| Peak magnetic field strength (T) at a depth of 2cm | Ranging from 0.46 – 0.55T depending on coil capabilities. | 0.5T | Substantially equivalent with no new or different questions of safety or effectiveness than the predicate device. |
| Peak magnetic field gradient dB/dt (kT/s) at a depth of 2cm | Ranging from 9 – 12 kT/s depending on coil capabilities | 11 kT/s |
PERFORMANCE DATA
| Items | New device | Predicate device | Statement of equivalence |
|---|---|---|---|
| Electrical Safety & Electromagnetic Compatibility | Complies with IEC60601-1 and IEC60601-1-2 | Complies with IEC60601-1 and IEC60601-1-2 | Same |
| Quality & Risk standards | Company complies with ISO 13485:2016 and ISO 14971:2019 | Company complies with ISO 13485:2016 and ISO 14971:2019 |
Page 11 of 12
Page 16
Page 12 of 12
Traditional 510(k) Premarket Submission
MagVenture TMS Therapy System
TONICA ELEKTRONIK A/S
VII. PERFORMANCE TESTING SUMMARY
Non-Clinical Performance Testing and Performance Standards
The MagVenture TMS Therapy System has been tested and complies with the following recognized electrical safety and performance standards:
- IEC 60601-1: General safety and essential performance requirements.
- IEC 60601-1-2: Electromagnetic compatibility compliance.
- IEC TR 60601-4-2: Electromagnetic immunity: performance of medical electrical equipment and medical electrical systems
- ISO 13485:2016 & ISO 14971:2019: Quality and risk management compliance.
Additionally, computational modeling (SimNIBS v4.0.1) has been used to compare the electric field strength of the MagVenture coils against the predicate device.
Clinical Performance Data
No clinical performance data were included in this submission.
VIII. PERFORMANCE TESTING SUMMARY
The MagVenture TMS Therapy System is substantially equivalent to the NeuroStar Advanced Therapy System (K230029) in terms of intended use, indications for use, treatment parameters, principles of operation, and overall technological characteristics. Differences between the devices—such as coil design, cooling method, and pulse width—do not raise new or different questions of safety and effectiveness. The Beam F3 Marking Plate provides an alternative, validated method for coil positioning, which is functionally equivalent to the standard 5.5 cm method used in TMS treatments.
Conclusion: The MagVenture TMS Therapy System, with the proposed modifications, maintains substantially equivalent safety, effectiveness, and intended use as the predicate device. The modifications do not introduce new or different questions of safety or effectiveness.
Therefore, the device is substantially equivalent to the NeuroStar Advanced Therapy System (K230029).
§ 882.5805 Repetitive transcranial magnetic stimulation system.
(a)
Identification. A repetitive transcranial magnetic stimulation system is an external device that delivers transcranial repetitive pulsed magnetic fields of sufficient magnitude to induce neural action potentials in the prefrontal cortex to treat the symptoms of major depressive disorder without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on any antidepressant therapy.(b)
Classification. Class II (special controls). The special control is FDA's “Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation System.” See § 882.1(e) for the availability of this guidance document.